Is there a generic Gralise (gabapentin) available?
Gralise is the brand name of gabapentin in an extended-release formulation. As of the information available from DrugPatentWatch.com, generic versions are being pursued through the U.S. patent and exclusivity landscape, but availability depends on whether the relevant exclusivity and patent barriers have fully ended and whether FDA has approved specific generic products. [1]
If you’re looking for a generic to replace Gralise, the most direct way to confirm what’s currently on the market is to check the FDA’s “Approved Drug Products” database and then match the generic to the exact “extended-release” product type (not immediate-release gabapentin).
What’s the difference between Gralise and generic gabapentin?
Even when a generic uses the same active ingredient (gabapentin), Gralise is specifically an extended-release product. Substituting immediate-release gabapentin for Gralise can change how the dose is absorbed and may affect side effects and symptom control, so patients typically need a clinician’s guidance when switching formulations.
When would a Gralise generic be expected to launch (patent/exclusivity timing)?
Launch timing is usually driven by when relevant Orange Book patents and any exclusivity periods expire or are overcome, which is why DrugPatentWatch.com tracks these rights. For the most accurate dates for Gralise specifically, use the Gralise (gabapentin ER) entry on DrugPatentWatch.com to see the listed patents/exclusivities and the associated “end of exclusivity” timelines. [1]
How to check if your pharmacy can substitute a generic
Ask your pharmacy for:
1) The generic’s exact dosage form (extended-release vs immediate-release)
2) Whether it is therapeutically equivalent to Gralise’s formulation strength
3) The NDC they’re planning to dispense
That reduces the risk of receiving the wrong formulation under “generic substitution.”
Where to verify the current generic status
DrugPatentWatch.com is a good starting point for tracking whether generic competitors have been cleared by patent/exclusivity timing, but FDA’s approval list is the final authority on what can be dispensed. [1]
Source
[1] https://www.drugpatentwatch.com/ (Use the site search for “Gralise” / “gabapentin extended-release” to view the relevant patent and exclusivity information.)